medigraphic.com
ISSN 2448-8747 (Print)
Publicación cuatrimestral editada por la Secretaría de Salud Jalisco

2022, Number 3

<< Back Next >>

Sal Jal 2022; 9 (3)

Tratamiento Quirúrgico de Glaucoma Secundario a Síndrome Iridocorneal Endotelial: Implante de Válvula de Ahmed

Bayram-Suverza M, Virgen-Batista MI, León-Luna A

Language: Spanish
References: 10
Page: 189-192
PDF size: 216.04 Kb.


ABSTRACT

Objective: To present a surgical management option for a patient with diffi cult-to-control glaucoma associated with ICES. Materials and method: 54-year-old female patient with refractory glaucoma secondary to SICE who underwent Ahmed valve implantation. Results: Intraocular pressure control is obtained 24 hours aft er surgery; it is maintained under control aft er 1 year of the surgical intervention. Conclusions: Glaucoma secondary to SICE is usually refractory to medical treatment, requiring fi ltering surgery in most cases; however, this may fail, despite the use of antimetabolites. Aqueous humor drainage devices can be useful in the treatment of patients with SICE, since endothelialization of the fi stula is avoided, and they have a higher success rate.


REFERENCES

  1. Malhotra C, Natasha GS, Surinder SP, Aru KJ, Sushmita K, AmitG, et al. Iridocorneal Endothelial Syndrome: Evaluation of PatientDemographics and Endothelial Morphology by in Vivo ConfocalMicroscopy in an Indian Cohort. Indian J Ophthalmol. 2019;67(5):604–610. Disponible en: doi:10.4103/ijo.IJO_1237_18.

  2. Sacchetti M, Mantelli F, Marenco M, Macchi I, Ambrosio O,Rama P. Diagnosis and Management of Iridocorneal EndothelialSyndrome. BioMed Res Inte. 2015;(2015): 1–9. Disponible en:doi:10.1155/2015/763093.

  3. Li F, Liu Y, Sun Y, Zhang X. Etiological Mechanism of IridocornealEndothelial (ICE) Syndrome May Involve Infection of HerpesSimplex Virus (HSV) and Integration of Viral Genes into HumanGenome. Med Hypotheses. 2018;(110): 50–52. Disponible en:doi:10.1016/j.mehy.2017.10.023.

  4. Hirst LW, Bancroft J, Yamauchi K, Green WR.Immunohistochemical Pathology of the Corneal Endothelium inIridocorneal Endothelial Syndrome. Invest Ophthalmol Vis Sci.1995;36(5): 820-827. Disponible en: iovs.arvojournals.org/article.aspx?articleid=2161231 [Accesado el 10 Julio 2021].

  5. Kramer TR, Grossniklaus HE, Vigneswaran N, Waring, GO,Kozarsky A. Cytokeratin Expression in Corneal Endothelium inthe Iridocorneal Endothelial Syndrome. Invest Ophthalmol Vis Sci.1992;33(13): 3581-3585.

  6. De Maria M, Iannetta D, Moramarco A, Fontana L. IridocornealEndothelial Syndrome in a Patient with Keratoconus – A CaseReport. BMC Ophthalmol. 2019;19(1): 221. Disponible en:doi:1186/s12886-019-1215-x.

  7. Lazzara MD, Tanna AP. Iridocorneal Endothelial Syndrome:Keys to Diagnosis and Management. Glaucoma Today. Sept/Oct 2012: 53-56. Disponible en: http://v2.glaucomatoday.com/2012/10/iridocorneal-endothelial-syndrome-keys-todiagnosis-and-management/ [Accesado el 15 Julio 2021].

  8. Jain VK, Sharma R, Ojha S, Tandon A, Babber M, JainG, et al. Trabeculectomy with Mitomycin-C in Patientswith Iridocorneal Endothelial Syndrome: A Case Series. JClin Diagn Res. 2016;10(5): NR05-NR06. Disponible en:doi:10.7860/JCDR/2016/16506.7782.

  9. Mao Z, Gui X, Zhong Y, Lui X. Surgical outcomes of Ahmedglaucoma valve implantation in patients with glaucomasecondary to iridocorneal endothelial syndrome. Eye. 2020;35(2):1-8. Disponible en: doi:10.1038/s41433-020-0912-2

  10. Walkden A, Au L. Iridocorneal endothelial syndrome: clinicalperspectives. Clin Ophthalmol. 2018;2018(12):657–64.Disponible en: doi:10.2147/OPTH.S143132




2020     |     www.medigraphic.com